Your browser doesn't support javascript.
loading
A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer.
Liu, Qian; Guo, Lijuan; Qi, Hongyan; Lou, Meng; Wang, Rui; Hai, Boning; Xu, Kailun; Zhu, Lijun; Ding, Yongfeng; Li, Chen; Xie, Lingdan; Shen, Jing; Xiang, Xueping; Shao, Jimin.
Afiliación
  • Liu Q; Department of Pathology & Pathophysiology, and Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Guo L; Department of Pathology & Pathophysiology, and Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Qi H; Department of Pathology & Pathophysiology, and Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Lou M; Zhejiang University Cancer Center, Key Laboratory of Disease Proteomics of Zhejiang Province, Key Laboratory of Cancer Prevention and Intervention of China National Ministry of Education, Zhejiang University School of Medicine, Hangzhou, China.
  • Wang R; Department of Pathology & Pathophysiology, and Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Hai B; Zhejiang University Cancer Center, Key Laboratory of Disease Proteomics of Zhejiang Province, Key Laboratory of Cancer Prevention and Intervention of China National Ministry of Education, Zhejiang University School of Medicine, Hangzhou, China.
  • Xu K; Department of Pathology & Pathophysiology, and Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhu L; Department of Pathology & Pathophysiology, and Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Ding Y; Department of Pathology & Pathophysiology, and Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Li C; Zhejiang University Cancer Center, Key Laboratory of Disease Proteomics of Zhejiang Province, Key Laboratory of Cancer Prevention and Intervention of China National Ministry of Education, Zhejiang University School of Medicine, Hangzhou, China.
  • Xie L; Key Laboratory of Pancreatic Disease of Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Shen J; Department of Pathology & Pathophysiology, and Cancer Institute of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Xiang X; Key Laboratory of Pancreatic Disease of Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Shao J; Department of Human Genetics, Zhejiang University School of Medicine, Hangzhou, China.
Cell Death Dis ; 12(7): 683, 2021 07 07.
Article en En | MEDLINE | ID: mdl-34234118

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinonas / Ribonucleósido Difosfato Reductasa / Proteínas Tirosina Quinasas / Neoplasias Colorrectales / Transactivadores / Proteínas de Ciclo Celular / Inhibidores Enzimáticos / Técnicas de Silenciamiento del Gen / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Cell Death Dis Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinonas / Ribonucleósido Difosfato Reductasa / Proteínas Tirosina Quinasas / Neoplasias Colorrectales / Transactivadores / Proteínas de Ciclo Celular / Inhibidores Enzimáticos / Técnicas de Silenciamiento del Gen / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Cell Death Dis Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido